Advertisement

World Journal of Surgery

, Volume 11, Issue 4, pp 418–425 | Cite as

Progress in gastric cancer surgery in Japan and its limits of radicality

  • Keiichi Maruyama
  • Kenzo Okabayashi
  • Taira Kinoshita
Progress Symposium—Advances in Surgical Oncology

Abstract

Radical surgery of gastric cancer has become more widely utilized in Japan. Topics explored in gastric cancer surgery include the extended lymph node dissection guided by the node staining method with India ink, left upper abdominal organs exenteration for advanced cancer of the upper stomach, and pancreaticoduodenectomy for advanced cancer of the lower stomach. Through the progress of surgical treatment as well as that of the early detection system, the treatment results have been improved. Using the data from nationwide registrations (5,706 and 11,845 cases) and those from the National Cancer Center Hospital (3,176 cases), the 5-year survival rate of total primary resected cases was 44.3% in the first period (1963–1966), 56.3% in the second period (1969–1973), and 61.6% in the third period (1971–1985). Between the first and the third period, the 5-year survival rate of patients with stage 2 cancer increased from 60.6% to 71.7%, and that of stage 3 increased from 32.7% to 44.3%; however, the limits of radical surgery were also clarified, especially in patients with peritoneal dissemination, liver metastasis, distant lymph node metastasis, and diffusely infiltrating carcinoma (Borrmann type 4). For such patients, chemotherapy, hormonal therapy, immunotherapy, radiotherapy, and hyperthermia should possibly be employed in hopes of improving treatment result.

Keywords

Periodo Peritoneal Dissemination Distant Lymph Node Extended Lymph Node Improve Treatment Result 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Résumé

La chirurgie radicale pour traiter le cancer gastrique est devenue plus aggressive au fil des ans. Les thèmes a atteindre furent les suivants: dissection ganglionnaire étendue quidée par la méthode de coloration des ganglions à l'encre indienne, exentération des organes de la partie haute de l'abdomen pour le cancer évolué haut situé, et duodéno-pancréatectomie pour le cancer bas situé. Grâce aux progrès du traitement chirurgical et aux méthodes de détection précoce les résultats du traitement se sont améliorés. Employant les données du registre national (5,706 et 11,845 cas) et ceux du Centre National Hospitalier du Cancer (3,176 cas), le taux total de survie à 5 ans des cas réséqués a été de 44.3% de 1963 à 1966, de 56.3% de 1969 à 1973, et de 61.6% de 1971 à 1985. Entre la première et la troisième période, le taux de survie à 5 ans du cancer stade II s'est élevé de 60.6% à 71.7%, et celui du stade III de 32.7% à 44.3%. En outre, les limites de la chirurgie radicale ont été précisées spécialement chez les malades qui présentent une carcinose péritonéale, des métastases hépatiques, des métastases ganglionnaires à distance ou un cancer infiltrant diffus (Borrmann type IV). Chez de tels sujets la chimiothérapie, l'hormonothérapie, l'immunothérapie, la radiothérapie, l'hyperthermie doivent être également employées pour essayer d'améliorer les résultats du traitement.

Resumen

La cirugía radical del cancer gástrico se ha extendido en el Japón. Tópicos recientes sobre cirugía del cáncer gástrico han sido la disección ganglionar amplia guiada por “el método de tinción ganglionar con tinta china,” “la exenteración de los órganos abdominales superiores izquierdos” para cáncer avanzado, y la pancreatoduodenectomía para los cánceres avanzados inferiores. Gracias al progreso en el tratamiento quirúrgico, así como en el sistema de detección precoz, se ha logrado mejorar los resultados terapéuticos. Utilizando los datos de registros nacionales (5,706 y 11,845 casos) y los del Hospital Centro Nacional de cáncer (3,176 casos), la tasa de supervivencia a 5 a∼nos del total de casos de resección primaria fue de 44.3% en el primer periodo (1963–1966), de 56.3% en el segundo periodo (1969–1973), y de 61.6% en el tercer periodo (1971–1985). Entre el primera y el tercer periodo la tasa de supervivencia a 5 anos para los estados 2 ascendió de 60.6% a 71.7%, y la de los estados 3 de 32.7% a 44.3%. Sin embargo, hemos tenido que aceptar los límites de la cirugía en cuanto a radicalidad, especialmente en pacientes con metástasis peritoneales, metástasis hepáticas, metástasis ganglionares distales y cáncer del tipo 4 (Borrman tipo 4, carcinoma de infiltración difusa). Para tales pacientes la quimioterapia, la terapia hormonal, la inmunoterapia, la radioterapia, y la hipertemia son modalidades adicionales que deben ser utilizadas con el fin de mejorar los resultados terapéuticos.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Maruyama, K.: Surgical treatment and end results of gastric cancer. In Standard Treatment of Gastric Cancer (UICC manual), Berlin-Heidelberg-New York, Springer-Verlag, 1987Google Scholar
  2. 2.
    Maruyama, K.: A new dissection technique of superior pancreatic lymph nodes, pancreas preserving radical gastrectomy. Jpn. J. Gastroenterol. Surg.12:961, 1979Google Scholar
  3. 3.
    Sawai, K., Takahashi, S., Kato, G., Takenaka, A., Tokuda, H., Hagiwara, A., Takahashi, T.: Endoscopic injection of activated carbon particle (CH44) for extended lymphadenectomy of gastric cancer. Jpn. J. Gastroenterol. Surg.18:912, 1985Google Scholar
  4. 4.
    Ohashi, I., Kajitani, T.: Radical operation for advanced upper gastric cancer. In Gastric Cancer Surgery (The Latest Therapy), vol. 3, Tokyo, Igaku Kyoiku Shuppan, 1986, pp. 344–350Google Scholar
  5. 5.
    Maruyama, K., Okabayashi, K., Kinoshita, T.: Radical operation for advanced gastric cancer. In Gastric Cancer Surgery (The Latest Therapy), vol. 3, Tokyo, Igaku Kyoiku Shuppan, 1986, pp. 358–367Google Scholar
  6. 6.
    Nishi, M., Kajitani, T.: Pancreaticoduodenectomy against gastric cancer. Rinsho-geka32:887, 1970Google Scholar
  7. 7.
    Miyazaki, I., Yonemura, Y.: Radical operation for advanced lower gastric cancer. In Gastric Cancer Surgery (The Latest Therapy), vol. 3, Tokyo, Igaku Kyoiku Shuppan, 1986, pp. 376–383Google Scholar
  8. 8.
    Nimura, Y.: Radical operation for advanced lower gastric cancer. In Gastric Cancer Surgery (The Latest Therapy), vol. 3, Tokyo, Igaku Kyoiku Shuppan, 1986, pp. 384–391Google Scholar
  9. 9.
    Japanese Research Society for Gastric Cancer: The general rules for the gastric cancer study in surgery and pathology. Jpn. J. Surg. 11:127, 1981Google Scholar
  10. 10.
    Japanese Research Society for Gastric Cancer, National Cancer Center: The Report of Treatment Results of Stomach Carcinoma in Japan (1963–1966), Tokyo, National Cancer Center, 1977Google Scholar
  11. 11.
    Japanese Research Society for Gastric Cancer, National Cancer Center: The Report of Treatment Results of Stomach Carcinoma in Japan (1969–1973), Tokyo, National Cancer Center, 1983Google Scholar
  12. 12.
    Koga, S., Hamazoe, R.: Continuous hyperthermic peritoneal perfusion for cancer. In Gastric Cancer Surgery (The Latest Therapy), vol. 3, Tokyo, Igaku Kyoiku Shuppan, 1986, pp. 525–529Google Scholar
  13. 13.
    Takahashi, T., Hagiwara, A., Ito, T.: Intraabdominal administration of mitomycin C adsorbed on activated carbon for management of carcinomatous peritonitis. Jpn. J. Cancer Chemother.11:1550, 1984Google Scholar
  14. 14.
    Okuyama, K., Isono, K., Onoda, S., Ochiai, T., Yamamoto, Y., Koide, Y., Hanaoka, A., Satoh, H.: Clinical studies on effective treatment for gastric cancer patients with synchronous hepatic metastasis. J. Jpn. Soc. Cancer Ther.19:763, 1984Google Scholar
  15. 15.
    Kitaoka, K., Ohkura, H., Yoshida, S.: Combination therapy of mitomycin C, Tegafur and Nolvadex for schirrous gastric cancer. Shokaki-geka Semin.21:50, 1985Google Scholar

Copyright information

© Société Internationale de Chirurgie 1987

Authors and Affiliations

  • Keiichi Maruyama
    • 1
  • Kenzo Okabayashi
    • 1
  • Taira Kinoshita
    • 1
  1. 1.Gastric Surgery DivisionNational Cancer Center HospitalTokyoJapan

Personalised recommendations